The high-risk price of these therapies is vast in excess of two million pounds often. But you do have to offset that with the costs of long-term chronic disease, which these patients would otherwise have. It's a massive challenge that we're facing at the moment and we really need to find new ways to ensure that patients in need can access these therapies. Many people have looked into innovative reimbursement strategies and payment strategies for these high-cost therapies.
Ian Sample speaks to Guardian science correspondent Hannah Devlin about the latest developments and debates about gene editing to emerge from a summit at the Francis Crick Institute in London. The summit heard from the first person with sickle cell disease to be treated with a technique known as Crispr. He also hears from Prof Claire Booth about ensuring these cutting edge treatments are made available to everyone who needs them. Help support our independent journalism at
theguardian.com/sciencepod